We are live on ! Find out more
GRI

GRI Bio
GRI

7 hedge funds and large institutions have $185K invested in GRI Bio in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

273% more capital invested

Capital invested by funds: $49.7K → $185K (+$136K)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

17% more funds holding

Funds holding: 6 → 7 (+1)

0.96% more ownership

Funds ownership: 1.54% → 2.51% (+0.96%)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$46.2K
2
VF
Virtu Financial
New York
+$21.9K
3
UBS Group
UBS Group
Switzerland
+$14.7K
4
TSS
Two Sigma Securities
New York
+$11.3K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$11.7K
2
HF
HRT Financial
New York
-$5K
3
TRCT
Tower Research Capital (TRC)
New York
-$685

GRI Hedge Fund Activity: Q4 2024 in Review

7 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q4 2024, worth a combined $185K — up 273% from $49.7K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new GRI positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $46.2K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $11.7K sold.

  • 7 institutional investors held GRI Bio (GRI) as of Q4 2024, up from 6 in Q3 2024.
  • Funds reported $185K of GRI Bio stock for Q4 2024, up 273% quarter-over-quarter.
  • 3 funds opened new GRI Bio positions in Q4 2024 and 2 closed out, a net change of +1 holder.
  • The largest GRI Bio buyer in Q4 2024 was Geode Capital Management, an estimated $46.2K added.
  • The largest GRI Bio seller in Q4 2024 was Susquehanna International Group, an estimated $11.7K sold.

Based on aggregated 13F filings for Q4 2024.